Vermillion, Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance outcomes for women in the United States. The company has market cap of $82.85 million. It is developing novel diagnostic tests for gynecologic disease with focus on ovarian cancer. It currently has negative earnings. The companyÂ’s products include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor.
Analysts expect First Republic Bank (NYSE:FRC) to report $1.05 EPS on April, 12.They anticipate $0.04 EPS change or 3.96% from last quarter’s $1.01 EPS. FRC’s profit would be $169.86 million giving it 23.04 P/E if the $1.05 EPS is correct. After having $1.10 EPS previously, First Republic Bank’s analysts see -4.55% EPS growth. The stock increased 0.13% or $0.13 during the last trading session, reaching $96.77. About 1.22 million shares traded. First Republic Bank (NYSE:FRC) has risen 29.07% since March 20, 2017 and is uptrending. It has outperformed by 12.37% the S&P500.
The stock decreased 0.72% or $0.01 during the last trading session, reaching $1.38. About 29,496 shares traded. Vermillion, Inc. (VRML) has risen 36.92% since March 20, 2017 and is uptrending. It has outperformed by 20.22% the S&P500.
Oracle Investment Management Inc holds 2.9% of its portfolio in Vermillion, Inc. for 9.83 million shares. Birchview Capital Lp owns 2.46 million shares or 2.29% of their US portfolio. Moreover, Morgens Waterfall Vintiadis & Co Inc has 1.51% invested in the company for 1.00 million shares. The New York-based Trellus Management Company Llc has invested 0.29% in the stock. Essex Investment Management Co Llc, a Massachusetts-based fund reported 216,607 shares.